About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 6614 record(s)
Req # A-2022-000775
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-106142-617, Deputy Ministerial Meeting with the Canadian Agency for Drugs and Technologies in Health.Organization: Health Canada
January 2025
Req # A-2022-000813
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-106142-617, Deputy Ministerial Meeting with the Canadian Agency for Drugs and Technologies in Health.Organization: Health Canada
January 2025
Req # A-2022-001055
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-106142-617, Deputy Ministerial Meeting with the Canadian Agency for Drugs and Technologies in Health.Organization: Health Canada
January 2025
Req # A-2023-000007
Adverse Drug Reaction (ADR) for GAMMAGARD S/D. Report number: E2B_06062081. ADRs for LANSOPRAZOLE. Report numbers: 001024427, 001024306, E2B_06029716, E2B_06037365, E2B_06056291, E2B_06069484, E2B_06080220.Organization: Health Canada
January 2025
Req # A-2023-000039
Adverse Drug Reactions (ADRs). Report numbers: E2B_06112909, 001026648, E2B_06057113, E2B_06113700, 001023643, 001023612, E2B_06090942, 001024930, 001025712, E2B_06055699.Organization: Health Canada
January 2025
Req # A-2023-000136
Adverse Drug Reaction (ADR). Report number: E2B_06129890.Organization: Health Canada
January 2025
Req # A-2023-000486
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-103759-468, Meeting with the Paramedic Association of Canada.Organization: Health Canada
January 2025
Req # A-2023-000741
Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_00951469, E2B_01063984, E2B_01208513, E2B_01238057, E2B_01352293, E2B_01333181, E2B 01439922, E2B 01889662, E2B_01863278.Organization: Health Canada
January 2025
Req # A-2023-000798
Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_03103879, E2B_03101878, E2B_02913252, E2B_03161744, E2B_03189743, 000678085, E2B_03184247, 000671634, 000631525, 000645867.Organization: Health Canada
January 2025
Req # A-2023-001374
Adverse Drug Reactions (ADRs). Report numbers: E2B_06659207, E2B_06029092.Organization: Health Canada
January 2025